Research Article
Improving the Lung Cancer Clinical Trial Development by Incorporating Competing Risk Factors
| | Immunotherapy () | | Chemotherapy () | value | Pembrolizumab () | Camrelizumab () | Atezolizumab () | Nivolumab () | | |
| Characteristic | | | | | | | Age, median (range) | 63 (50-77) | 66 (40-75) | 67 (43-78) | 68 (39-75) | 62 (40-75) | 0.4158 | Men | 9 | 16 | 16 | 15 | 35 | 0.7747 | Women | 3 | 7 | 3 | 4 | 10 | | ECOG performance status score | | | | | | | 0 | 4 | 6 | 7 | 5 | 15 | 0.7162 | 1 | 8 | 17 | 12 | 14 | 30 | | Tumor histological features | | | | | | | Squamous | 4 | 8 | 6 | 6 | 14 | 0.8420 | Nonsquamous | 8 | 15 | 13 | 13 | 31 | | TNM stage | | | | | | | III | 5 | 7 | 7 | 6 | 15 | 0.9189 | IV | 7 | 16 | 12 | 13 | 30 | |
|
|